0000950170-24-038630.txt : 20240329
0000950170-24-038630.hdr.sgml : 20240329
20240329160511
ACCESSION NUMBER: 0000950170-24-038630
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240327
FILED AS OF DATE: 20240329
DATE AS OF CHANGE: 20240329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Okazaki Jason A
CENTRAL INDEX KEY: 0001807214
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35005
FILM NUMBER: 24804130
MAIL ADDRESS:
STREET 1: C/O ASSEMBLY BIOSCIENCES, INC.
STREET 2: 331 OYSTER POINT BLVD, FOURTH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0001426800
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TWO TOWER PLACE
STREET 2: 7TH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (833) 409-4583
MAIL ADDRESS:
STREET 1: TWO TOWER PLACE
STREET 2: 7TH FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC
DATE OF NAME CHANGE: 20080211
4
1
ownership.xml
4
X0508
4
2024-03-27
0001426800
ASSEMBLY BIOSCIENCES, INC.
ASMB
0001807214
Okazaki Jason A
C/O ASSEMBLY BIOSCIENCES, INC.
TWO TOWER PLACE, 7TH FLOOR
SOUTH SAN FRANCISCO
CA
94080
true
true
false
false
CEO and President
false
Common Stock
2024-03-27
4
S
false
392
12.87
D
14180
D
The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
Reflects equitable adjustment of the number of shares of common stock beneficially owned by the reporting person as a result of a 1-for-12 reverse stock split of the Issuer's common stock effected February 9, 2024, which is exempt from reporting pursuant to Rule 16a-9.
/s/ John O. Gunderson, as Attorney-in-Fact
2024-03-29